Everforth Inc quarterly report, Q1 FY2007

Business Context and Reporting Period

Company: On Assignment, Inc. (Note: Input metadata referenced "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: A diversified professional staffing firm operating in four segments: Life Sciences, Healthcare, Physician, and IT and Engineering. The quarter was defined by two major strategic acquisitions: VISTA Staffing Solutions (Physician segment) on January 3, 2007, and Oxford Global Resources (IT and Engineering segment) on January 31, 2007.

Key Financial Metrics

Metric Q1 2007 Q1 2006
Revenues $122,629,000 $66,723,000
Gross Profit $37,460,000 $16,984,000
Gross Margin 30.5% 25.5%
Operating Income $3,199,000 $198,000
Net Income $911,000 $302,000
Diluted EPS $0.03 $0.01
Cash from Operations $4,633,000 $2,470,000
Cash & Equivalents (End of Period) $22,577,000 $22,770,000
Total Debt (Notes Payable) $145,820,000 $0
Working Capital $67,254,000 $135,501,000

Material Changes vs. Prior Period

  • Revenue Growth: Consolidated revenue increased 83.8% year-over-year. This is primarily driven by the inclusion of the Physician and IT and Engineering segments from the VISTA and Oxford acquisitions, respectively. Organic growth in legacy segments (Life Sciences and Healthcare) was 19.7% and 5.9% respectively.
  • Profitability: Operating income surged to $3.2 million from $198,000. Gross margin expanded 500 basis points to 30.5%, largely due to the high-margin IT and Engineering segment (37.1% margin) and improved bill/pay spreads in legacy segments.
  • Balance Sheet Transformation: Total assets nearly doubled to $371.6 million, driven by $170.1 million in new goodwill and $55.9 million in intangible assets from acquisitions. Total liabilities increased to $192.1 million, primarily due to a new $165 million senior secured credit facility ($145 million term loan) used to finance the Oxford acquisition.
  • Expense Structure: Selling, General, and Administrative (SG&A) expenses more than doubled to $34.3 million. This increase is attributed to the acquisitions, higher stock-based compensation ($1.1 million vs $0.5 million), and a significant increase in amortization of intangible assets ($4.2 million vs $0.2 million).

Guidance, Outlook, and Risks

  • Outlook: Management expects continued revenue growth in the Physician and IT and Engineering segments as demand exceeds supply. The company anticipates leveraging SG&A synergies across the new and existing segments.
  • Capital Expenditures: The company expects to incur approximately $5.5 million to $6.1 million in capital expenditures in 2007 for technology initiatives and fixed asset purchases.
  • Debt Covenants: The company is in compliance with all financial covenants of its new credit facility, including minimum leverage and interest coverage ratios. The term loan requires quarterly principal payments and potential additional paydowns based on excess cash flow.
  • Interest Rate Risk: The company entered into an interest rate swap to fix the rate on $73 million of its debt at 4.9425% starting June 30, 2007, mitigating exposure to floating rate increases.
  • Contingencies: There are potential earn-out obligations of up to $8 million for VISTA and $12 million for Oxford contingent on 2007 and 2008 financial performance. Additionally, the company is partially self-insured for workers' compensation and medical malpractice, creating exposure to loss variability.
  • Controls: Internal controls for the newly acquired subsidiaries (VISTA and Oxford) are being implemented and are excluded from the current period's effectiveness evaluation, with full implementation expected by March 31, 2008.

Investor Verification Checklist

  • Acquisition Integration: Verify the progress of integrating VISTA and Oxford systems and the realization of projected SG&A synergies.
  • Debt Service Capacity: Monitor cash flow generation to ensure compliance with the new credit facility's leverage ratios and mandatory principal paydowns.
  • Earn-Out Performance: Track the financial performance of VISTA and Oxford against the targets required to trigger the $20 million in potential additional consideration.
  • Goodwill Impairment: Assess the $187.2 million goodwill balance, particularly given the rapid expansion and the need for annual impairment testing under FAS 142.
  • Legacy Segment Health: Confirm that organic growth in Life Sciences and Healthcare segments remains resilient despite the significant reduction in utilization by a major Nurse Travel customer mentioned in the filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.